Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Immuneering EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Immuneering's EPS for the twelve months ending Sep 30, 2026 was -$1.03. For fiscal 2025 it was -$1.27. The highest annual figure on record is -$1.27 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.27 | – |
| FY2024 | Dec 31, 2024 | -$2.04 | – |
| FY2023 | Dec 31, 2023 | -$1.88 | – |
| FY2022 | Dec 31, 2022 | -$1.91 | – |
| FY2021 | Dec 31, 2021 | -$2.46 | – |
| FY2020 | Dec 31, 2020 | -$3.44 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.37 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.27 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.21 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.18 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.38 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.40 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.42 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.58 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.49 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.47 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.49 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.52 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.43 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.43 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.51 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.50 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.49 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.44 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.49 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.47 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.61 | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.26 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.18 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.89 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.73 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?